|
⚲
|
| Keyboard |
| LV Management Group LLC
✚
|
|
|---|---|
| CRD # | 165640 |
| SEC # | 802-77222 |
| CIK # | 0001681884 |
| AUM | |
| Employees | |
| Phone | 317-429-0141 |
| Address | 333 N Alabama St Indianapolis, IN 46204-2034 |
| Source | [IAPD] [EDGAR] [Website] |
| Total AUM ($) |
|---|
| Type | Form D Funds | Date | Sold | AUM |
|---|---|---|---|---|
| VC | Lilly Ventures Fund I LLC | 2012-10-01 | 327.0 M |
| AUM Breakdown | Accounts | AUM ($) |
|---|---|---|
| By Client Type | ||
| (a) Individuals (other than high net worth individuals) | 0 | 0.0 |
| (b) Individuals (high net worth individuals) | 0 | 0.0 |
| (c) Banking or thrift institutions | 0 | 0.0 |
| (d) Investment companies | 0 | 0.0 |
| (e) Business development companies | 0 | 0.0 |
| (f) Pooled investment vehicles | 0 | 0.0 |
| (g) Pension and profit sharing plans | 0 | 0.0 |
| (h) Charitable organizations | 0 | 0.0 |
| (i) State or municipal government entities | 0 | 0.0 |
| (j) Other investment advisers | 0 | 0.0 |
| (k) Insurance companies | 0 | 0.0 |
| (l) Sovereign wealth funds and foreign official institutions | 0 | 0.0 |
| (m) Corporations or other businesses not listed above | 0 | 0.0 |
| (n) Other | 0 | 0.0 |
| Total | 0 | 0.0 |
| By Discretionary | ||
| Discretionary | 0 | 0.0 |
| Non-Discretionary | 0 | 0.0 |
| Total | 0 | 0.0 |
| By Non-United States Persons | ||
| Non-United States Persons | 0.0 | |
| United States Persons | 0.0 | |
| Total | 0 | 0.0 |
| EDGAR Form | CIK | 2011 - 2026 |
|---|---|---|
| 3 | [0001681884] | |
| 4 | [0001681884] |
| Form 3/4/5 Subject | 2011 - 2026 |
|---|---|
| Surface Oncology Inc | |
| LV Management Group LLC | |
| Hall Steven Edward | |
| Torres S Edward | |
| Lilly Ventures Fund I LLC | |
| Rein Therapeutics Inc | |
| Protagonist Therapeutics Inc |
| Insider Transaction (Form 3/4/5) | Date | Action | Shares | Price | Value ($) |
|---|---|---|---|---|---|
|
Surface Oncology Inc SURF
Series A Preferred Stock · derivative
|
2018-04-23 | Conversion | 7,000,000 | ||
|
Surface Oncology Inc SURF
Common Stock
|
2018-04-23 | Buy | 266,000 | $15.00 | 3,990,000 |
|
Surface Oncology Inc SURF
Common Stock
|
2018-04-23 | Conversion | 3,181,817 | ||
|
Rein Therapeutics Inc ALRN
Series E-2 Preferred Stock · derivative
|
2017-07-05 | Conversion | 1,907,373 | $0.00 | |
|
Rein Therapeutics Inc ALRN
Series F Preferred Stock · derivative
|
2017-07-05 | Conversion | 1,443,972 | $0.00 | |
|
Rein Therapeutics Inc ALRN
Series E-3 Preferred Stock · derivative
|
2017-07-05 | Conversion | 1,654,411 | $0.00 | |
|
Rein Therapeutics Inc ALRN
Common Stock
|
2017-07-05 | Conversion | 844,987 | ||
|
Rein Therapeutics Inc ALRN
Common Stock
|
2017-07-05 | Buy | 250,000 | $15.00 | 3,750,000 |
|
Rein Therapeutics Inc ALRN
Series D Preferred Stock · derivative
|
2017-07-05 | Conversion | 3,390,885 | $0.00 | |
|
Protagonist Therapeutics Inc PTGX
Common Stock
|
2016-08-16 | Conversion | 630,541 | ||
|
Protagonist Therapeutics Inc PTGX
Series C Preferred Stock · derivative
|
2016-08-16 | Conversion | 9,841,333 | $0.00 | |
|
Protagonist Therapeutics Inc PTGX
Series B Preferred Stock · derivative
|
2016-08-16 | Conversion | 9,142,857 | $0.00 | |
|
Protagonist Therapeutics Inc PTGX
Series A Preferred Stock · derivative
|
2016-08-16 | Conversion | 3,000,000 | $0.00 | |
|
Protagonist Therapeutics Inc PTGX
Common Stock
|
2016-08-16 | Conversion | 206,896 | ||
|
Protagonist Therapeutics Inc PTGX
Common Stock
|
2016-08-16 | Buy | 583,333 | $12.00 | 6,999,996 |
|
Protagonist Therapeutics Inc PTGX
Common Stock
|
2016-08-16 | Conversion | 678,712 |